Antibiogram of Escherichia coli and Klebsiella spp. Detected by Vitek ESBL Test / 대한임상미생물학회지
Korean Journal of Clinical Microbiology
; : 47-51, 2003.
Article
in Ko
| WPRIM
| ID: wpr-63713
Responsible library:
WPRO
ABSTRACT
BACKGROUND: Extended-spectrum beta -lactamase (ESBL) producing Escherichia coli and Klebsiella spp. isolates are clinically resistant to all the beta -lactams except carapenems and cephamycins. This study was to determine the prevalence of ESBL producing E. coli and Klebsiella spp. and the rates and trends of resistance to extended-spectrum beta -lactams and other antimicrobial agents in ESBL producing E. coli and Klebsiella spp.. METHODS: During the periods of 2002, a total 2,551 clinical isolates of E. coli & Klebsiella spp. were collected from patients of the Samsung medical center, Seoul, Korea. Antimicrobial susceptibility test and determination of ESBL production were performed by Vitek GNS-433 card. RESULTS: 151/1,594 (9.5%) of E. coli isolates, 128/896 (14.3%) of K. pneumoniae isolates and 11/61 (18.0%) of K. oxytica were ESBL producing strains. Resistance to cefoxitin and cefepime were 2.4% and 13.4% in ESBL producing isolates. Imipenem had excellent activity against E .coli and Klebsiella spp. (100% susceptible). CONCLUSION: In this study, ESBL-producing E. coli and Klebsiella spp were more resistant to beta -lactams including cefepime than ESBL non-producing E. coli and Klebsiella spp.. ESBL producing E. coli and Klebsiella spp. showed a high level of co-resistance with aminoglycosides and fluoroquinolones. Imipenem showed the highest level of activity against E. coli and Klebsiella spp..
Key words
Full text:
1
Index:
WPRIM
Main subject:
Pneumonia
/
Microbial Sensitivity Tests
/
Cefoxitin
/
Cephamycins
/
Imipenem
/
Prevalence
/
Fluoroquinolones
/
Escherichia
/
Escherichia coli
/
Seoul
Type of study:
Prevalence_studies
Limits:
Humans
Country/Region as subject:
Asia
Language:
Ko
Journal:
Korean Journal of Clinical Microbiology
Year:
2003
Type:
Article